Text Size
Trial record 2 of 2 for:    "Bronchiolitis obliterans organizing pneumonia"
Previous Study | Return to List | Next Study

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

This study has been terminated.
(Terminated due to slow accrual.)
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00656916
First received: April 7, 2008
Last updated: March 29, 2012
Last verified: March 2012
History of Changes
  Purpose

The goal of this clinical research study is to compare lung function of patients who inhale steroids in the early stages of post-transplant constrictive bronchiolitis (PTCB) to patients who continue with standard of care.


Condition Intervention Phase
Bronchiolitis
 Drug: Fluticasone Propionate
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Study of Early Treatment With Inhaled Corticosteroids Versus Observation for Patients Who Have Decreased Lung Function Status Post Allogeneic Stem Cell Transplantation

Resource links provided by NLM:

MedlinePlus related topics: Steroids
U.S. FDA Resources

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Lung Function Non-deterioration Rate [ Time Frame: Baseline and three months ] [ Designated as safety issue: No ]
    Lung function non deterioration rate defined by change of forced expiratory volume in one second (FEV1) of < 20%. FEV1, maximal amount of air forcefully exhaled in 1 second, converted to percentage of normal, calculated from a pulmonary function test (PFT) performed at baseline and three months.


Enrollment: 1
Study Start Date: March 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fluticasone Propionate
440 micrograms twice daily by oral inhalation.
 Drug: Fluticasone Propionate
440 micrograms twice daily by oral inhalation.
No Intervention: Observational Group
Comparator group, no intervention.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients >/=18 years of age.
  2. Patients must be engrafted and at least 80 days post allogeneic hematopoietic stem cell transplantation.
  3. New onset airflow obstruction defined as decline of forced expiratory volume in 1 second (FEV1) percent predicted >/= 15%.
  4. Total Lung Capacity (TLC) > 85% to rule out restrictive lung disease.
  5. Patient must be willing to comply with all study procedures and capable of signing informed consent.

Exclusion Criteria:

  1. Patients with active pulmonary infection.
  2. Patients with known hypersensitivity to corticosteroids
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00656916

Locations
United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Principal Investigator: Lara Bashoura, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
MD Anderson Cancer Center  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00656916     History of Changes
Other Study ID Numbers: 2007-0390
Study First Received: April 7, 2008
Results First Received: February 7, 2012
Last Updated: March 29, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Post-Transplant Constrictive Bronchiolitis
Bronchiolitis
Fluticasone Propionate
 Inhaled Corticosteroids
Lung Condition
PTCB

Additional relevant MeSH terms:
Bronchiolitis
Respiratory Insufficiency
Bronchitis
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Respiration Disorders
Fluticasone
Bronchodilator Agents
 Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Dermatologic Agents
Anti-Allergic Agents
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on June 13, 2013